1L	First line
2L	Second line
BOR	Best overall response
CI	Confidence interval
CONSORT	Consolidated Standards of Reporting Trials
CR	Complete response
D	Docetaxel
DCR	Disease control rate
DoR	Duration of response
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organization for Research and Treatment of Cancer
G	Gemcitabine
HR	Hazard ratio
IHC	Immunohistochemistry
IRR	Infusion-related reaction
ITT	Intention to treat
IV	Intravenous
KM	Kaplan–Meier
LMS	Leiomyosarcoma
mBPI-sf	Modified Brief Pain Inventory-short form
NONMEM	Nonlinear Mixed Effects Modelling software
O	Olaratumab
ORR	Objective response rate
OS	Overall survival
PBO	Placebo
PDGF	Platelet-derived growth factor
PDGFR	Platelet-derived growth factor receptor
PFS	Progression-free survival
PK	Pharmacokinetics
PR	Partial response
PROs	Patient-reported outcomes
PS	Performance status
QLQ-C30	Quality of life questionnaire
RECIST	Response Evaluation Criteria in Solid Tumors
SAE	Serious adverse event
SD	Stable disease
STS	Soft tissue sarcoma
TEAE	Treatment-emergent adverse event